Spain’s leading business school in biopharmaceuticals, CESIF (Centro de Estudios Superiores de la Industria Farmacéutica), has signed a strategic partnership with Universitat CEU Abat Oliba (CEU UAO), a prestigious private university based in Barcelona.
About the Institutions
CESIF, part of the Metrodora Education Group, specializes in advanced training for the biopharmaceutical and healthcare sectors. With over 35 years of experience, it has trained more than 15,000 professionals through practical, industry-focused programs taught by active sector experts.
Universitat CEU Abat Oliba, founded in 1973 and part of Spain’s renowned CEU Foundation university network, offers excellence in fields like health sciences, business, law, and humanities. One of its three faculties focuses on Health and Life Sciences, emphasizing innovative research and real-world application.
Partnership Details
Announced on March 10, 2026, the agreement establishes a framework for joint development of high-level university programs in biopharmaceutical business management, strategy, and leadership.
Key objectives include:
- Creating Títulos Propios (own-degree titles) such as Master’s, Expert, and Specialist programs.
- Launching complementary, continuous, and lifelong learning initiatives.
- Bridging academia and industry through applied research tailored to biopharma needs like digitalization, biotech innovation, regulations, and sustainability.
Strategic Impact
CESIF CEO Clara Campos emphasized: “This alliance strengthens our commitment to linking academic knowledge with healthcare realities, delivering specialized training and impactful research for the industry and health system.”
CEU UAO Rector Arcadi Gual added: “Partnering with CESIF bolsters our dedication to top-tier health and life sciences education. Collaborating with industry-tied institutions drives innovative programs to transform biopharma.”
This collaboration positions Spain’s biopharma sector—a key economic driver with high innovation and skilled job creation—as a global leader amid rapid technological shifts.
